CGTX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Jim SimonsRenaissance Technologies $848k1.1M shares TrimQ1 2026 $460k $0.7595 $1.19
Ken GriffinCitadel Advisors $20k25.9k shares TrimQ1 2026 $198k $0.7595 $1.19
Mario GabelliGAMCO Investors $15k20k shares TrimQ1 2026 $12k $0.7595 $1.19
Jim SimonsRenaissance Technologies $1.3M969.5k shares AddQ4 2025 $346k $1.35 $1.19
Jim SimonsRenaissance Technologies $933.4K AddQ3 2025 $933k -- $1.19
Jim SimonsRenaissance Technologies $6.4K AddQ2 2025 $6.4k -- $1.19

News

globenewswire.comCognition Therapeutics Participating in Upcoming Investor Conferencesglobenewswire.comJun 1

globenewswire.comCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosisglobenewswire.comMay 21

globenewswire.comCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodiesglobenewswire.comMay 14

globenewswire.comCognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Updateglobenewswire.comMay 7

defenseworld.netCognition Therapeutics (NASDAQ:CGTX) CEO Lisa Ricciardi Acquires 9,175 Shares of Stockdefenseworld.netApr 21

Trade CGTX

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

CEO: Lisa Ricciardi
IPO Date: Oct 8, 2021

Market Data

Open: $1.21
High: $1.23
Low: $1.12
Volume: 686.8K
52W High: $3.83
52W Low: $0.25

Valuation

Market Cap: $85M
Enterprise Value: $54M

Financials

Free Cash Flow: $-25M
Revenue: $0
Net Income: $-23M
Cash: $37M
Debt: $638k

Events

EarningsAug 6

EPS est. -0.06